U.S. Markets closed

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
16.60-0.08 (-0.48%)
At close: 4:00PM EDT

16.99 +0.39 (2.35%)
After hours: 6:09PM EDT

People also watch
ZIOPFOLDACADCLDXACHN
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Revenue12/31/201612/31/201512/31/2014
Total Revenue146,691135,05775,334
Cost of Revenue33,20629,24522,732
Gross Profit113,485105,81252,602
Operating Expenses
Research Development150,84293,23679,696
Selling General and Administrative45,85340,02835,942
Non Recurring---
Others---
Total Operating Expenses---
Operating Income or Loss-83,210-27,452-63,036
Income from Continuing Operations
Total Other Income/Expenses Net1,326422242
Earnings Before Interest and Taxes-81,884-27,030-62,794
Interest Expense19,9775,2015,581
Income Before Tax-101,861-32,231-68,375
Income Tax Expense1,162--
Minority Interest---
Net Income From Continuing Ops-103,023-32,231-68,375
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-103,023-32,231-68,375
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-103,023-32,231-68,375